The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Olanzapine Versus Divalproex Sodium for the Treatment of Acute Mania and Maintenance of Remission: A 47-Week Study
Abstract
OBJECTIVE: Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex. METHOD: This 47-week, randomized, double-blind study compared flexibly dosed olanzapine (5-20 mg/day) to divalproex (500-2500 mg/day) for manic or mixed episodes of bipolar disorder (N=251). The only other psychoactive medication allowed was lorazepam for agitation. The primary efficacy instrument was the Young Mania Rating Scale; a priori protocol-defined threshold scores were > or =20 for inclusion, < or =12 for remission, and > or = 15 for relapse. Analytical techniques included mixed model repeated-measures analysis of variance for change from baseline, Fisher's exact test (two-tailed) for categorical comparisons, and Kaplan-Meier estimates of time to events of interest. RESULTS: Over 47 weeks, mean improvement in Young Mania Rating Scale score was significantly greater for the olanzapine group. Median time to symptomatic mania remission was significantly shorter for olanzapine, 14 days, than for divalproex, 62 days. There were no significant differences between treatments in the rates of symptomatic mania remission over the 47 weeks (56.8% and 45.5%, respectively) and subsequent relapse into mania or depression (42.3% and 56.5%). Treatment-emergent adverse events occurring significantly more frequently during olanzapine treatment were somnolence, dry mouth, increased appetite, weight gain, akathisia, and high alanine aminotransferase levels; those for divalproex were nausea and nervousness. CONCLUSIONS: In this 47-week study of acute bipolar mania, symptomatic remission occurred sooner and overall mania improvement was greater for olanzapine than for divalproex, but rates of bipolar relapse did not differ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 3×
“Severity of symptoms was assessed with the 11-item Young Mania Rating Scale (17), the 21-item Hamilton Depression Rating Scale (20), the severity of illness rating from the Clinical Global Impressions (CGI) scale for bipolar disorder (21), and the Positive and Negative Syndrome Scale (22).”
MethodResultDevelopment of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
Bowden, C. L. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.481 · Cited by 678
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Self-citationTohen, M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.9.841 · Cited by 539
Self-citationOutcome in Mania: A 4-Year Prospective Follow-up of 75 Patients Utilizing Survival Analysis
Tohen, M. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240026005 · Cited by 532
Self-citationTohen, M. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.220 · Cited by 524
Self-citationValproatereatment of Acute Mania: A Placebo-Controlled
Pope, H. G. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810250064008 · Cited by 460
Comparison of Standard and Low Serum Levels of Lithium for Maintenance Treatment of Bipolar Disorder
Gelenberg, A. J., Kane, J. M., Keller, M. B., Lavori, P., Rosenbaum, J. F., Cole, K., & Lavelle, J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212201 · Cited by 448
Keller, M. B. (1986) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1986.03370220100035 · Cited by 318
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · PubMed · Cited by 317
Twelve-Month Outcome After a First Hospitalization for Affective Psychosis
Strakowski, S. M., Keck, P. E., McElroy, S. L., West, S. A., Sax, K. W., Hawkins, J. M., Kmetz, G. F., Upadhyaya, V. H., Tugrul, K. C., & Bourne, M. L. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.1.49 · Cited by 296
Long-Term Olanzapine Treatment: Weight Change and Weight-Related Health Factors in Schizophrenia
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0204 · Cited by 269
Lithium versus carbamazepine in the maintenance treatment of bipolar disorders – a randomised study
Greil, W., Ludwig-Mayerhofer, W., Erazo, N., Schöchlin, C., Schmidt, S., Engel, R. R., Czernik, A., Giedke, H., Müller-Oerlinghausen, B., Osterheider, M., et al. (1997) · Journal of Affective Disorders · doi:10.1016/s0165-0327(96)01427-9 · Cited by 261
Olanzapine Versus Divalproex in the Treatment of Acute Mania
Tohen, M., Baker, R. W., Altshuler, L. L., Zarate, C. A., Suppes, T., Ketter, T. A., Milton, D. R., Risser, R., Gilmore, J. A., Breier, A., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1011 · Cited by 256
Self-citationSuppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., & Rush, A. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1164 · Cited by 238
Self-citationWeight change associated with valproate and lamotrigine monotherapy in patients with epilepsy
Biton, V., Mirza, W., Montouris, G., Vuong, A., Hammer, A. E., & Barrett, P. S. (2001) · Neurology · doi:10.1212/wnl.56.2.172 · Cited by 234
Pharmacologic activation of limbic structures and neuroimaging studies of emotions.
Beasley, C. M., Tollefson, G. D., & Tran, P. V. (1997) · PubMed · Cited by 197
Suppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., & Rush, A. J. (2003) · Focus · doi:10.1176/foc.1.1.37 · Cited by 197
Self-citationMajor Affective Disorder as a Recurrent Illness: A Critical Review
Zis, A. P. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780080009002 · Cited by 190
Zajecka, J. M., Weisler, R., Sachs, G., Swann, A. C., Wozniak, P., & Sommerville, K. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1210 · Cited by 170
Self-citationThe McLean First-episode Psychosis Project: Six-month Recovery and Recurrence Outcome
Tohen, M. F., Stoll, A. L., Strakowski, S. M., Faedda, G. L., Mayer, P., Goodwin, D. C., Kolbrener, M., & Madigan, A. M. (1992) · Schizophrenia Bulletin · doi:10.1093/schbul/18.2.273 · Cited by 135
Self-citationCzekalla, J., Beasley, C. M., Dellva, M. A., Berg, P. H., & Grundy, S. L. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0310 · Cited by 121
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.
Czekalla, J., Kollack‐Walker, S., & Beasley, C. M. (2001) · PubMed · Cited by 77
Epidemiology of Bipolar Disorder
Tohen, M. F., & Angst, J. (2002) · Wiley eBooks · doi:10.1002/0471234311.ch17 · Cited by 75
Self-citationECNP Consensus Meeting March 2000 Nice
Montgomery, D. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00140-1 · Cited by 41
Efficacy of Divalproex vs Lithium and Placebo in the Treatment of Mania
Bowden, C. L. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360044034 · Cited by 1
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Randomised controlled trials report that olanzapine (Tohen et al., 2003c, 2012), quetiapine (Calabrese et al., 2005b; McElroy et al., 2010; Thase, 2006; Young et al., 2010) and lurasidone (Loebel et al., 2014a, 2014b) are effective treatments for bipolar depression, but these studies have…”
BackgroundGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Tohen, M., Greil, W., Calabrese, J. R., Sachs, G. S., Yatham, L. N., Oerlinghausen, B. M., Koukopoulos, A., Cassano, G. B., Grunze, H., Licht, R. W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1281 · Cited by 365
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Metadata
- Authors
- Tohen, M., Ketter, T. A., Zarate, C. A., Suppes, T., Frye, M., Altshuler, L., Zajecka, J., Schuh, L. M., Risser, R. C., Brown, E., & Baker, R. W.
- Venue
- American Journal of Psychiatry
- Published
- 2003-07-01
- Volume
- 160
- Issue
- 7
- Pages
- 1263-1271
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2121339106
- Cited by
- 342
- References
- 32
- FWCI
- 24.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.